Clinical Data Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off BioSpaceSanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a "measured risk."Clinical DataImmunology & InflammationRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) BioSpace Sanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a “measured risk.” Clinical DataImmunology & InflammationRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Sanofi immune drug hopeful posts mixed results in mid-stage testsNext: In the face of tariffs, FDA-approved drug manufacturing deals are shifting to Europe Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
